Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

1.6%

1 terminated/withdrawn out of 64 trials

Success Rate

93.3%

+6.7% vs industry average

Late-Stage Pipeline

20%

13 trials in Phase 3/4

Results Transparency

1 of 14 completed trials have results

Key Signals

22 recruiting1 with results

Enrollment Performance

Analytics

N/A

17(36.2%)

Phase 2

14(29.8%)

Phase 4

8(17.0%)

Phase 3

5(10.6%)

Phase 1

2(4.3%)

Early Phase 1

1(2.1%)

47Total

N/A(17)

Phase 2(14)

Phase 4(8)

Phase 3(5)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (64)

Showing 20 of 64 trials

NCT07853885Phase 4Not Yet Recruiting

Intraosseous Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty

Role: lead

NCT06073730Phase 3Completed

Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

Role: lead

NCT07712848Phase 3Recruiting

DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

Role: lead

NCT07706699Not ApplicableCompleted

Low-Current Stimulation for Recurrent Laryngeal Nerve Protection During Thyroid Surgery

Role: lead

NCT07604688Recruiting

Multicenter Registry Study of Patients With Intracranial Dural Arteriovenous Fistulas in China

Role: collaborator

NCT07608224Phase 2Not Yet Recruiting

HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC

Role: collaborator

NCT05129904Active Not Recruiting

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

Role: collaborator

NCT07587671Not ApplicableNot Yet Recruiting

Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis

Role: collaborator

NCT07241793Phase 2Recruiting

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Role: collaborator

NCT04518475Phase 4Recruiting

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Role: collaborator

NCT07412171Phase 2Not Yet Recruiting

NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

Role: collaborator

NCT06484374Not ApplicableRecruiting

A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic guidanCe for Hemorrhagic Stroke: Large Basal Ganglia Hemorrhage

Role: collaborator

NCT07406139Phase 4Recruiting

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

Role: collaborator

NCT06107582Recruiting

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

Role: collaborator

NCT03384277Phase 4Completed

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Role: collaborator

NCT03664518Phase 2Completed

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

Role: collaborator

NCT01719692Not ApplicableCompleted

Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia

Role: collaborator

NCT07237828Not ApplicableNot Yet Recruiting

Drain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR

Role: collaborator

NCT07239674Phase 3Not Yet Recruiting

Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC

Role: collaborator

NCT04669496Phase 2Active Not Recruiting

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Role: collaborator